PIN29 Cost Effectiveness Analysis of Addition of Telaprevir or Boceprevir to Standard Therapy Versus Standard Therapy Alone for the Treatment of Previously Untreated Chronic Hepatitis-C Virus Genotype 1 Infection
Jun 1, 2012, 00:00 AM
10.1016/j.jval.2012.03.1305
https://www.valueinhealthjournal.com/article/S1098-3015(12)01370-8/fulltext
Section Title :
Infection
Section Order :
839
First Page :
A242
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)01370-8&doi=10.1016/j.jval.2012.03.1305